MedTrace Logo

Combination of TATE and PD-1 Inhibitor in Liver Cancer

NCT03259867 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-04-16

No results posted yet for this study

Summary

This is a multi-center, open-label phase IIA study that investigates the preliminary efficacy of Trans-arterial Tirapazamine Embolization (TATE) treatment of liver cancer followed by a PD-1 checkpoint inhibitor (nivolumab). Patients with two types of cancers will be enrolled, advanced hepatocellular carcinoma (HCC),and metastatic gastric cancer. All enrolled patients need to have liver lesions and have progressed on a prior immune checkpoint inhibitor.

Conditions

Interventions

DRUG

Nivolumab Injectable Product

a PD-1 immune check inhibitor

COMBINATION_PRODUCT

Trans-arterial tirapazamine embolization

Embolization with Lipiodol and Gelfoam

Sponsors & Collaborators

  • Teclison Ltd.

    lead INDUSTRY

Principal Investigators

  • Nadine Abi-Jaoudeh, MD · UC Irvine Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-01
Primary Completion
2026-12-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03259867 on ClinicalTrials.gov